ImmunityBio (IBRX) Stock Price & Analysis

IBRX$6.16+0.18 +3.01%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$6.55BEnterprise value$10.20BRevenue (TTM)$165.79MMarket position—

Score

65
Bullish
Value
63
Quality
33
Growth
100

AI Analysis

Snapshot

ImmunityBio is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 65/100) in Biotechnology. Under the hood: revenue compounding ~1033% annually over recent years. Street targets still imply ~127% upside.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

63
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

100
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

33
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

ImmunityBio, Inc. (IBRX) last printed $6.16. Equity value is $6.55B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$44,000.00$45,000.00$47,000.00$43,000.00$605,000.00$934,000.00$240,000.00$622,000.00$14.74M$113.29M

About

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.

ImmunityBio (IBRX) Stock Price & Analysis

IBRX price $6.16 +0.18 +3.01%

Ticker
IBRX
Price
$6.16
Change
+0.18 +3.01%
Market cap
$6.55B
Forward P/E
11.58
Dividend yield
0.00%
Beta
0.12
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
65
Value
63
Quality
33
Growth
100

Stocklytics score rationale: value 63, quality 33, growth 100.

AI Score 30. ImmunityBio, Inc. has a high market cap of approximately $9.46 billion but is facing significant financial challenges, with a net profit margin of -5.99% and a price-to-sales ratio of 57.1, indicating overvaluation relative to its revenue

Insights · Forecast · Financials · Learn

Stocklytics home · Screener